Hints and tips:
...But Michael Mina, a former Harvard professor who is now chief medical officer at testing company eMed, suspects it could happen in 20 to 30 per cent of patients....
...asks Mina. Perhaps an even trickier task will be deciding who gets the limited supply in the short term....
...David Maris of Wells Fargo asked whether the company had become “less predictable” following the months of dramatic acquisitions and transformation....
...David Maris, a pharmaceuticals analyst at Wells Fargo, says he has “mixed feelings” about such tactics....
...“The problem is the whole company is built on a syllogistic fallacy,” says Mr Maris, referring to Valeant’s belief that it can succeed in pharmaceuticals without finding new medicines....
...David Maris, analyst at Wells Fargo, says shareholders should be “particularly wary” of Valeant’s adjusted earnings-per-share figures....
...David Maris, analyst at CLSA, notes there is a looming drought of new generics coming in 2014 after the next wave of expirations passes....
...Last week, Biovail filed a suit claiming $4.6bn in damages from Gradient, SAC Capital, the $7bn hedge fund founded by Steven Cohen, and David Maris, a pharmaceuticals analyst at Bank of America....
...Mr Maris is a pharmaceutical analyst who made his name by taking bearish positions on companies such as Elan, the Irish drug company....
International Edition